Neurogene
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
535 W 24th St Fl 5, New York, New York, ...Phone Number
(855) 508-3568Website
www.neurogene.comRevenue
-Stock Symbol
NGNEIndustry
About Neurogene
Neurogene's mission is to develop life-altering genetic medicines for patients and their families affected by rare, devastating neurological diseases. Our lead programs use adeno-associated virus (AAV) vector-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options currently exist. Neurogene is also developing novel gene therapy technologies to advance treatments for complex neurological diseases that conventional gene therapy cannot successfully address.Explore more
Neurogene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Neurogene
Compare insights from companies similar to Neurogene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Neurogene Tech Stack
A closer look at the technologies used by Neurogene
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Neurogene
Sign Up For FreeTo access detailed company insights
Neurogene's mission is to develop life-altering genetic medicines for patients and their families affected by rare, devastating neurological diseases. Our lead programs use adeno-associated virus (AAV) vector-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. We partner with leading academic researchers, p... Read More
